Literature DB >> 32334799

Elevated neutrophil to lymphocyte ratio is associated with poor long-term survival and graft failure after lung transplantation.

Aravind Krishnan1, Joshua Hsu1, Jinny S Ha1, Stephen R Broderick1, Pali D Shah2, Robert Sd Higgins1, Christian A Merlo2, Errol L Bush3.   

Abstract

PURPOSE: We aimed to assess the prognostic value of Neutrophil to Lymphocyte Ratio (NLR) on long-term outcomes and graft dysfunction after lung transplantation.
METHODS: We retrospectively reviewed all patients receiving a lung transplant at our institution from 2011 to 2014. The primary exposure was elevated NLR at the time of transplant, defined by NLR>4. The primary outcomes were graft failure and three-year all-cause mortality. Multivariate logistic regression and Kaplan-Meier survival analysis were used to analyze outcomes.
RESULTS: 95 patients were included. 40 patients (42%) had an elevated NLR. Elevated NLR was associated with graft failure (OR: 4.7 [1.2-18.8], p = 0.02), and three-year mortality (OR: 5.4 [1.3-23.2], p = 0.03) on multivariate logistic regression. Patients with elevated NLR demonstrated significantly lower survival on Kaplan-Meier analysis (50% versus 74%, p = 0.02). The c-statistic for our multivariate model was 0.91.
CONCLUSION: Elevated neutrophil to lymphocyte ratio is associated with poor long-term survival and graft failure after lung transplantation.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarker; Immunology; Lung transplantation; Outcomes; Transplantation

Year:  2020        PMID: 32334799     DOI: 10.1016/j.amjsurg.2020.04.007

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  1 in total

1.  Survival and prognostic analysis of T-cell lymphoblastic lymphoma patients treated with dose-adjusted BFM-90 regimen.

Authors:  Hui Yu; Lan Mi; Fei Qi; Xing Wang; Yingying Ye; Miaomiao Li; Dedao Wang; Ning Ding; Xiaogan Wang; Yuqin Song; Jun Zhu; Yan Xie
Journal:  Aging (Albany NY)       Date:  2022-04-10       Impact factor: 5.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.